Trial Profile
A Study Assessing Outcomes and Toxicity of Self-Funded Pembrolizumab in Patients with Non-Melanoma Solid Cancers Treated at Chris O'Brien Lifehouse.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2017 New trial record